Abvc notes new report that estimates global retinal surgical instruments market to grow to $2.46 billion by 2028

-- growth to benefit abvc's vitargus medical device product -- fremont, ca, july 18, 2022 (globe newswire) -- via newmediawire – abvc biopharma, inc. (nasdaq: abvc), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, cns, and ophthalmology, today announced that, according to a recent study by bosson research, the global retinal surgical instruments market, valued at usd 1.59 billion in 2021, is expected to reach usd2.46 billion by the end of 2028, growing at a cagr of 6.08% between 2022 and 2028.  this growth is expected to benefit abvc's development of its medical device, vitargus, a gel-like substance that aims to help the eye maintain a round shape and keep the retina in place during and after retina re-attachment surgery.
ABVC Ratings Summary
ABVC Quant Ranking